Tamed Malaria Parasite Vaccine Passes Early Trial (VIDEO)
Caption
A proof-of-concept clinical trial shows that genetic engineering of the malaria parasite by the precise removal of three genes (called GAP3KO) creates a parasite strain that infects humans, but cannot cause malaria disease, and stimulates the immune system to mount protective responses. This video shows the procedure used to deliver the GAP3KO vaccine to human subjects through infected mosquito bites as well as a microscopic video of the motile parasite forms that constitute the vaccine.
Credit
Sebastian Mikolajczak, Center for Infectious Disease Research
Usage Restrictions
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.
License
Licensed content